BLA 125496 · Recordati Rare Diseases, Inc.
Sylvant
Siltuximab · Injection · Interleukin-6 Antagonist
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 5, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Apr 23, 2014
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
43
5 Phase 3, 8 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Immunology and inflammation
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Siltuximab" as an intervention, any sponsor and status, largest first.
- A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)Pivotal-lookingNot yet recruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07908537 · 564 participants (planned) · Start Dec 7, 2026 · Primary completion Dec 8, 2031
Drug: Gocatamig; Durvalumab and 1 more · For: Small Cell Lung Cancer
- SILtuximab in Viral ARds (SILVAR) StudyPivotal-lookingTerminated
RECORDATI GROUPIndustry
NCT04616586 · 555 participants · Start Nov 13, 2020 · Primary completion Apr 1, 2021
Drug: Siltuximab · For: Acute Respiratory Distress Syndrome; Lung Diseases; Pneumonia and 2 more
Sites: Lansing, Michigan; Charlotte, North Carolina
- Treatment of COVID-19 Patients With Anti-interleukin DrugsPivotal-lookingCompleted
University Hospital, GhentAcademic, hospital or other
NCT04330638 · 342 participants · Start Apr 3, 2020 · Primary completion Dec 20, 2020
Drug: Anakinra; Siltuximab and 1 more · For: COVID-19
Sites: Bruges, Belgium; Brussels, Belgium; Edegem, Belgium · 15 sites in all
- A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)Pivotal-lookingRecruiting
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07570173 · 340 participants (planned) · Start May 18, 2026 · Primary completion Oct 18, 2033
Drug: MK-1045; Blinatumomab and 7 more · For: B-cell Acute Lymphoblastic Leukemia
Sites: Toronto, Canada; Copenhagen, Denmark; Aarhus Nord, Denmark · 30 sites in all
- A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple MyelomaPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT00401843 · 307 participants · Start Nov 28, 2006 · Primary completion Aug 16, 2011
Drug: Siltuximab; Bortezomib and 2 more · For: Multiple Myeloma
Sites: Greenbrae, California; Los Angeles, California; Indianapolis, Indiana · 80 sites in all
- A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantPivotal-lookingRecruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT06679829 · 215 participants (planned) · Start Nov 6, 2024 · Primary completion Nov 2027
Drug: Siltuximab; Melphalan · For: Multiple Myeloma
Sites: Basking Ridge, New Jersey; Middletown, New Jersey; Montvale, New Jersey · 7 sites in all
- Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 PneumoniaPivotal-lookingCompleted
Judit Pich MartínezAcademic, hospital or other
NCT04329650 · 163 participants · Start Apr 15, 2020 · Primary completion Feb 26, 2021
Drug: Siltuximab; Dexamethasone · For: COVID-19
Sites: Badalona, Spain; Barcelona, Spain; Salamanca, Spain · 4 sites in all
- A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy ParticipantsPivotal-lookingCompleted
Centocor, Inc.Johnson & Johnson (Janssen) (JNJ)
NCT02074800 · 145 participants · Start Jun 2008 · Primary completion Jun 2009
Drug: CNTO 328 (Sp2/0-derived); CNTO 328 (CHO-derived) and 1 more · For: Healthy
Sites: Lincoln, Nebraska; Neptune City, New Jersey
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part B: Sylvant (Siltuximab) · HCPCS J2860
2024 spending
$12.6M
Beneficiaries
86
797 claims
Per beneficiary
$147,048
2024 ASP limit $152.62 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,576,949 |
| 2021 | $8,308,640 |
| 2022 | $11,681,692 |
| 2023 | $12,525,046 |
| 2024 | $12,646,138 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial.
van Rhee F, Wong RS, Munshi N, et al. · Lancet Oncol 2014 · Multicenter Study, Randomized Controlled Trial
- Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
Khan FA, Stewart I, Fabbri L, et al. · Thorax 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
van Rhee F, Rosenthal A, Kanhai K, et al. · Blood Adv 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
- Emerging immune targets for the treatment of multiple myeloma.
Sohail A, Mushtaq A, Iftikhar A, et al. · Immunotherapy 2018 · Research Support, N.I.H., Extramural, Systematic Review
- A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.
Kastrati K, Aletaha D, Burmester GR, et al. · RMD Open 2022 · Research Support, Non-U.S. Gov't, Systematic Review
- Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease.
Zhang L, Zhao AL, Duan MH, et al. · Blood 2019 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
Sponsor: Recordati Rare Diseases, Inc.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.